284 related articles for article (PubMed ID: 23026607)
1. Is isoniazid safe for liver transplant candidates with latent tuberculosis?
Stucchi RS; Boin IF; Angerami RN; Zanaga L; Ataide EC; Udo EY
Transplant Proc; 2012 Oct; 44(8):2406-10. PubMed ID: 23026607
[TBL] [Abstract][Full Text] [Related]
2. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period.
Jahng AW; Tran T; Bui L; Joyner JL
Transplantation; 2007 Jun; 83(12):1557-62. PubMed ID: 17589337
[TBL] [Abstract][Full Text] [Related]
3. Detection and management of latent tuberculosis in liver transplant patients.
Jafri SM; Singal AG; Kaul D; Fontana RJ
Liver Transpl; 2011 Mar; 17(3):306-14. PubMed ID: 21384513
[TBL] [Abstract][Full Text] [Related]
4. Chemoprophylaxis with isoniazid in liver transplant recipients.
Fábrega E; Sampedro B; Cabezas J; Casafont F; Mieses MÁ; Moraleja I; Crespo J; Pons-Romero F
Liver Transpl; 2012 Sep; 18(9):1110-7. PubMed ID: 22645064
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis.
Singh N; Wagener MM; Gayowski T
Transplantation; 2002 Sep; 74(6):892-5. PubMed ID: 12364876
[TBL] [Abstract][Full Text] [Related]
6. Isoniazid prophylaxis in liver transplant recipient with latent tuberculosis: Is it harmful for transplanted liver?
Ghayumi SMA; Shamsaeefar A; Motazedian N; Mashhadiagha A; Sayadi M; Nikeghbalian S; Malekhosseini SA
Transpl Infect Dis; 2022 Aug; 24(4):e13849. PubMed ID: 35579604
[TBL] [Abstract][Full Text] [Related]
7. Isoniazid hepatotoxicity in renal transplant recipients.
Antony SJ; Ynares C; Dummer JS
Clin Transplant; 1997 Feb; 11(1):34-7. PubMed ID: 9067692
[TBL] [Abstract][Full Text] [Related]
8. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
[TBL] [Abstract][Full Text] [Related]
9. Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area.
Moon HH; Park SY; Kim JM; Park JB; Kwon CHD; Peck KR; Kim SJ; Lee SK; Joh JW
Ann Transplant; 2017 Jun; 22():338-345. PubMed ID: 28579606
[TBL] [Abstract][Full Text] [Related]
10. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
[TBL] [Abstract][Full Text] [Related]
11. Is isoniazid for 6 months more cost-effective than isoniazid for 9 months?
Pina JM; Clotet L; Sala MR; Ferrer A; Arias C; Domínguez A
Int J Tuberc Lung Dis; 2012 Jun; 16(6):768-73. PubMed ID: 22508169
[TBL] [Abstract][Full Text] [Related]
12. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
Gray EL; Goldberg HF
Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
[TBL] [Abstract][Full Text] [Related]
13. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates.
de Castilla DL; Rakita RM; Spitters CE; Narita M; Jain R; Limaye AP
Transplantation; 2014 Jan; 97(2):206-11. PubMed ID: 24142036
[TBL] [Abstract][Full Text] [Related]
14. Liver transplantation without isoniazid prophylaxis for recipients with a history of tuberculosis.
Nagai S; Fujimoto Y; Taira K; Egawa H; Takada Y; Kiuchi T; Tanaka K
Clin Transplant; 2007; 21(2):229-34. PubMed ID: 17425750
[TBL] [Abstract][Full Text] [Related]
15. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers.
Wu SS; Chao CS; Vargas JH; Sharp HL; Martín MG; McDiarmid SV; Sinatra FR; Ament ME
Transplantation; 2007 Jul; 84(2):173-9. PubMed ID: 17667808
[TBL] [Abstract][Full Text] [Related]
16. Outcome of latent tuberculosis infection in solid organ transplant recipients over a 10-year period.
Sidhu A; Verma G; Humar A; Kumar D
Transplantation; 2014 Sep; 98(6):671-5. PubMed ID: 24825525
[TBL] [Abstract][Full Text] [Related]
17. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.
Esfahani K; Aspler A; Menzies D; Schwartzman K
Int J Tuberc Lung Dis; 2011 Oct; 15(10):1340-6. PubMed ID: 22283892
[TBL] [Abstract][Full Text] [Related]
18. Treatment of latent tuberculosis infection: An update.
Lobue P; Menzies D
Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
[TBL] [Abstract][Full Text] [Related]
19. Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting.
Conti A; Piaserico S; Gisondi P; Odorici G; Galdo G; Lasagni C; Pellacani G
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28547750
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy.
Vikrant S; Agarwal SK; Gupta S; Bhowmik D; Tiwari SC; Dash SC; Guleria S; Mehta SN
Transpl Infect Dis; 2005; 7(3-4):99-108. PubMed ID: 16390397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
